乳腺癌区域淋巴结照射日常实践中危及器官不可接受剂量的发生率
结果显示77.4%的病例满足所有危及器官约束,最常见的不可接受剂量为对侧乳腺(15.7%)和同侧肺V5(10.8%);多因素分析中调强放疗(OR 64.7)和淋巴结推量(OR 5.5)与更高的不可接受剂量率独立相关。
要点
- 日常实践中三维适形放疗±深吸气屏气的危及器官不可接受剂量率较低(7.9%)。
- 调强放疗与显著更高的危及器官不可接受剂量率独立相关(OR 64.7)。
- 内乳淋巴结照射和重建与否与不可接受剂量率无独立关联。
核心结论
- 三维适形放疗±深吸气屏气的危及器官不可接受剂量率低,且与内乳淋巴结照射或重建无独立关联。
- 调强放疗与显著更高的总体危及器官不可接受剂量率独立相关,临床医生在启动区域淋巴结照射计划时应知晓。
研究设计与样本
- 以NSABP B51/RTOG 1304临床剂量体积约束为基准,分析剂量体积直方图评估危及器官不可接受剂量发生率。
- 采用逻辑回归检验危及器官不可接受剂量与关键变量的关联。
主要发现
- 77.4%的病例满足所有危及器官约束。
- 最常见的危及器官不可接受剂量为对侧乳腺(n=32,15.7%)和同侧肺V5(n=22,10.8%)。
- 多因素分析中,调强放疗(OR 64.7;95%CI 20.8-201.5;P<.001)和淋巴结推量(OR 5.5;95%CI 1.1-27.1;P=.04)与更高的危及器官不可接受剂量率独立相关。
- 内乳淋巴结照射(OR 2.7;P=.35)和重建(OR 0.62;P=.33)与危及器官不可接受剂量率无独立关联。
- 三维适形放疗计划中,7.9%存在危及器官不可接受剂量。
关键数值与推荐
- 心脏约束:平均剂量>5 Gy定义为不可接受剂量。
- 同侧肺约束:V20>35%、V10>60%、V5>70%定义为不可接受剂量。
- 对侧肺约束:V5>15%定义为不可接受剂量。
- 对侧乳腺约束:V4.1>5%定义为不可接受剂量。
临床怎么用
- 日常临床中采用三维适形放疗±深吸气屏气时,危及器官不可接受剂量率较低。
- 使用调强放疗时应警惕危及器官不可接受剂量率显著升高,需仔细评估计划。
- 内乳淋巴结照射或重建的存在不应成为预期危及器官不可接受剂量升高的独立理由。
局限性
- 回顾性研究设计。
- 未报告其他潜在混杂因素或长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: As indications for regional nodal irradiation (RNI) for breast cancer have expanded, so too has scrutiny over potential late toxicity from radiotherapy. This emphasizes the need for careful radiation treatment planning to maximize the therapeutic ratio. We sought to evaluate how often unacceptable doses (UDs) to organs at risk (OARs) occur and the associated factors for patients receiving RNI in daily practice. METHODS AND MATERIALS: Treatment records of patients who received RNI from February 2012 to May 2015 were studied. The NSABP B51/RTOG 1304 clinical dose-volume constraints for targets/OARs receiving RNI were used as the benchmark. Dose-volume histograms were analyzed for the rate of ≥1 UD delivered to the following organs: heart, mean >5 Gy; ipsilateral lung, V20 >35%, V10 >60%, V5 >70%; contralateral lung (CL), V5 >15%; and contralateral breast, V4.1 >5%. Logistic regression was used to test the association between UDs to OAR and key variables. RESULTS: Two hundred three consecutive cases received RNI (105 left, 98 right), to the chest wall in 171 (84%) and to the internal mammary nodes in 170 (84%); 77.4% of cases met all OAR constraints. The most common OAR UDs were delivered to the contralateral breast (n = 32, 15.7%) and ipsilateral lung V5 (n = 22, 10.8%). On multivariate analysis, use of intensity modulated radiation therapy (odds ratio [OR], 64.7; 95% confidence interval, 20.8-201.5; P < .001) and use of nodal boost (OR, 5.5; 95% confidence interval, 1.1-27.1; P = .04), but not internal mammary node irradiation (OR, 2.7; P = .35) or reconstruction (OR, 0.62; P = .33), were independently associated with higher OAR UD rate. For 3-dimensional conformal radiation therapy plans, 7.9% had OAR UDs. CONCLUSION: The OAR UD rate with 3-dimensional conformal radiation therapy ± deep inspiration breath-hold in routine clinical practice is low and not independently associated with internal mammary node irradiation or reconstruction presence. Women treated with intensity modulated radiation therapy had a significantly higher overall OAR UD rate, and clinicians should be aware of this as they initiate RNI treatment planning.
引用
- Bazan J, DiCostanzo D, Kuhn K, et al. Likelihood of unacceptable normal tissue doses in breast cancer patients undergoing regional nodal irradiation in routine clinical practice. Pract Radiat Oncol. 2016. PMID: 28094211. doi:10.1016/j.prro.2016.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。